RCT BioVentures

RCT BioVentures is the venture capital and technology management arm of Research Corporation Technologies (RCT), an Arizona-based firm dedicated to commercializing early-stage life science innovations. The company operates a unique business model that integrates investment capital with active technology development and global licensing. RCT is widely recognized for its management of the Pichia pastoris protein expression platform, which has become an industry standard for the production of recombinant proteins and biologics. Their investment portfolio includes a broad range of therapeutics, medical devices, and diagnostics, typically targeting assets at the pre-clinical or early clinical stages. By providing both financial resources and strategic guidance, RCT BioVentures facilitates the transition of high-potential academic and startup discoveries into the commercial market.